Economic and microbiologic evaluation of single-dose vial extension for hazardous drugs

Journal of Oncology Practice

Volumn 8, Issue 4, 2012, Pages

  Rowe, Erinn C ^a   Savage, Scott W ^a   Rutala, William A ^a   Weber, David J ^a   Gergen Teague, Maria ^a   Eckel, Stephen F ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; INFLIXIMAB; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PEMETREXED; RITUXIMAB; TOPOTECAN; VINCRISTINE;

ARTICLE; DRUG COST; ECONOMIC EVALUATION; HAZARDOUS WASTE; HOSPITAL MANAGEMENT; HOSPITAL WASTE; MICROBIOLOGICAL EXAMINATION; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; SHELF LIFE; SINGLE DOSE VIAL; THEORETICAL MODEL; THEORETICAL STUDY; TIME; WASTE MANAGEMENT;

ANTINEOPLASTIC AGENTS; BACTERIA; COST SAVINGS; DRUG CONTAMINATION; DRUG PACKAGING; DRUG STORAGE; HAZARDOUS SUBSTANCES; HUMANS; RETROSPECTIVE STUDIES; STERILIZATION;

EID: 84870336790     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000488     Document Type: Article

References (16)

1. Gehrett BK: A prescription for drug shortages. JAMA 307:153-154, 2012
2. Rabin RC: Drug scarcity's dire cost, and some ways to cope. www.nytimes.com/2011/12/13/health/policy/the-personal-price-paid-for-shortages- of-doxil-and-other-drugs.html?pagewanted=all
3. Candy TA, Schneider PJ, Pederson CA: Impact of United States Pharmacopeia Chapter 797: Results of a national survey. Am J Health Syst Pharm 63:1336-1343, 2006 (Pubitemid 44116787)
4. US Pharmacopeial Convention: USP 31/NF 26: Pharmaceutical compounding-Sterile preparations: USP General Chapter 〈797〉. www.usp.org/usp-nf
5. US Pharmacopeial Convention: USP 34/NF 29: Antimicrobial effectiveness testing-USP General Chapter 〈51〉. www.usp.org/usp-nf
6. Metcalfe J: Microbiological quality of drug products after penetration of the container system for dose preparation prior to patient administration. http://clean-roomcloseout.com/Micro-quality.asp
7. Cundell A: Review of the media selection and incubation conditions for the compendial sterility and microbial limit tests. Pharm Forum 28:2034-2041, 2002
8. Vandenbroucke J, Robays H: Economic impact of the preparation scenario for cytotoxic drugs: An observational study. EJHP Pract 14:37-42, 2008
9. Connor TH, Anderson RW, Sessink PJ, et al: Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 56:1427-1432, 1999 (Pubitemid 29331357)
10. Wick C, Slawson M, Jorgenson J, et al: Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm 60:2314-2320, 2003 (Pubitemid 44712872)
11. De Prijck K, D'Haese E, Vandenbroucke J, et al: Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents. Lett Appl Microbiol 47:543-548, 2008
12. Favier B, Latour JC, Fuhnmann C: Viability of microorganisms in bags of cytotoxic drugs J Oncol Pharm Pract 6:167-171, 2001
13. Rowe E, Eckel S: Evaluating microbial growth in various antineoplastics and monoclonal antibodies. Presented at the 45th Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Anaheim, CA, December 5-9, 2010
14. Trissel L, Gentempo J, Saenz L, et al: Effect of two work practice changes on the microbial contamination rates of pharmacy: Compounded sterile preparations. Am J Health Syst Pharm 64:837-841, 2007 (Pubitemid 46625468)
15. Webster J, Radke E, George N, et al: Barrier properties and cost implications of a single versus a double wrap for storing instrument packs. Am J Infect Control 33:348-352, 2004 (Pubitemid 41074578)
16. AccessMED: Billing Medicare for discarded remainder drug. www.mckessonspecialtyhealth.com/accessservices/accessmed/documents/5.06. 2010%20Billing%20Medicare%20for%20Discarded%20Remainder%20Drug%20-%20sent%205.7. 10.pd